Pegvisomant: Balance after 10 years

Endocrinol Nutr. 2015 Oct;62(8):363-5. doi: 10.1016/j.endonu.2015.06.001. Epub 2015 Aug 1.

[Article in English, Spanish]

Authors

Ignacio Bernabeu¹, Mónica Marazuela²

Affiliations

¹ Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, España. Electronic address: ignacio.bernabeu.moron@sergas.es.
² Servicio de Endocrinología y Nutrición, Hospital Universitario de La Princesa, Madrid, España.

PMID: 26242927
DOI: 10.1016/j.endonu.2015.06.001

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Acromegaly / blood
Acromegaly / drug therapy*
Acromegaly / etiology
Adenoma / blood
Adenoma / complications
Adenoma / drug therapy*
Adenoma / surgery
Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Agents, Hormonal / adverse effects
Antineoplastic Agents, Hormonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Dose-Response Relationship, Drug
Female
Growth Hormone-Secreting Pituitary Adenoma / blood
Growth Hormone-Secreting Pituitary Adenoma / complications
Growth Hormone-Secreting Pituitary Adenoma / drug therapy*
Growth Hormone-Secreting Pituitary Adenoma / surgery
Human Growth Hormone / administration & dosage
Human Growth Hormone / adverse effects
Human Growth Hormone / analogs & derivatives*
Human Growth Hormone / therapeutic use
Humans
Hypophysectomy
Insulin-Like Growth Factor I / analysis
Male
Multicenter Studies as Topic
Observational Studies as Topic
Product Surveillance, Postmarketing
Receptors, Somatostatin / antagonists & inhibitors
Tumor Burden

Substances

Antineoplastic Agents, Hormonal
Receptors, Somatostatin
Human Growth Hormone
Insulin-Like Growth Factor I
pegvisomant